DexCom, Inc. (DXCM)
DexCom, Inc. is a Healthcare company in the S&P 500 and the Nasdaq 100, with a market capitalization of about $32.6 billion as of October 1, 2026.
- Ticker
- DXCM · Nasdaq
- Sector
- Healthcare
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus
- Market cap
- $32.6 billion
- Employees
- 11,000
- Headquarters
- San Diego, CA
- Fiscal year end
- December 31
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Financial statements
Nvevo shows DexCom, Inc.'s income statement, balance sheet, cash flow statement and key ratios as reported in its 10-K and 10-Q filings with the SEC, annually and quarterly, alongside price history, recent news and fair value models.
Other Healthcare companies
- Eli Lilly and Company (LLY)
- Johnson & Johnson (JNJ)
- AbbVie Inc. (ABBV)
- Merck & Co., Inc. (MRK)
- UnitedHealth Group Incorporated (UNH)
- Thermo Fisher Scientific Inc. (TMO)
- Amgen Inc. (AMGN)
- Gilead Sciences, Inc. (GILD)
Research another company · Market map · Stock screener · Compare companies